Indiglove Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 06-12-2024
- Paid Up Capital ₹ 2.00 M
as on 06-12-2024
- Company Age 5 Year, 4 Months
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 7.50 M
as on 06-12-2024
- Revenue 534.44%
(FY 2021)
- Profit 37.12%
(FY 2021)
- Ebitda 72.35%
(FY 2021)
- Net Worth 13.38%
(FY 2021)
- Total Assets 519.42%
(FY 2021)
About Indiglove Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 2.00 M.
The company currently has active open charges totaling ₹7.50 M.
Devansh Chakraborty and Sayantani Sen serve as directors at the Company.
- CIN/LLPIN
U52609WB2019PTC233791
- Company No.
233791
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Sep 2019
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Indiglove Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sayantani Sen  | Director | 13-Feb-2020 | Current |
| Devansh Chakraborty | Director | 05-Sep-2019 | Current |
Financial Performance of Indiglove Pharma.
Indiglove Pharma Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 534.44% increase. The company also saw a substantial improvement in profitability, with a 37.12% increase in profit. The company's net worth Soared by an impressive increase of 13.38%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Indiglove Pharma?
In 2021, Indiglove Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 30 Jun 2020 | ₹7.50 M | Open |
How Many Employees Work at Indiglove Pharma?
Unlock and access historical data on people associated with Indiglove Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Indiglove Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Indiglove Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
